Steglujan (ertugliflozin/sitagliptin) / Pfizer, Merck (MSD) - LARVOL DELTA

Comparison chart: Sodium-glucose cotransporter 2 (SGLT2) inhibitors. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Noninsulin drugs for type 2 diabetes. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Cost-Effectiveness Analysis of Oral Semaglutide As a Third-Line Treatment for Patients With Type 2 Diabetes Mellitus (ISPOR-EU 2025) - "Probabilistic sensitivity analyses (PSA) and scenario analyses were conducted. Oral semaglutide increased QALYs by 0.13 and 0.04 and costs by €571 and €692; the ICERs were €4,248 and €19,595 compared to liraglutide and dulaglutide. Oral semaglutide is a cost-effective option for T2DM patients who have received metformin or sulfonylurea combined with DPP-4 inhibitors, SGLT2 inhibitors, SGLT2+DPP-4 inhibitors, or insulin for six months but continue to experience inadequate glycemic control."

Clinical • Cost effectiveness • HEOR • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Molecular interactions of diabetes medications with alzheimer's related targets by molecular docking. (PubMed, J Diabetes Metab Disord) - "This study investigates the potential of two commonly prescribed diabetes medications, Ertugliflozin and Sitagliptin, to impact Alzheimer's disease-related factors...In this study, Metformin was utilized as the positive control ligand...By potentially inhibiting these factors, the drugs could exhibit a dual action, benefiting both diabetes and Alzheimer's. Further in vivo and clinical studies are needed to confirm these observations."

Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Diabetes • Hypoglycemia • Metabolic Disorders • Pain

Combination of Ertugliflozin And Sitagliptin Efficacy, Safety & Tolerability (CEASE Diabetes) Study (clinicaltrials.gov) - P=N/A | N=190 | Completed | Sponsor: Getz Pharma | Recruiting ➔ Completed | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Jul 2024

Trial completion • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

EVALUATING THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN AND SITAGLIPTIN COMBINATION THERAPY (TREVIA-R2®) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: CEASE DIABETES STUDY (ATTD 2025) - "In the 15 mg+100 mg group, weight decreased from 73.5 to 70.8 kg, SBP from 130 to 120 mmHg, HbA1c from 8.55% to 7.1%, FBS from 148.5 to 111 mg/dL, and RBS from 168.5 to 148 mg/dL. Between-group analysis showed significant differences in SBP (p < 0.001) and FBS (p = 0.034).Conclusions The Ertugliflozin + Sitagliptin combination therapy demonstrated efficacy in improving glycemic control, lowering blood pressure, and promoting weight loss in Pakistani T2DM patients, indicating its potential as a viable treatment option."

Clinical • Combination therapy • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Case of MODY Due to a Rare Activating Variant in the ABCC8 Gene (ENDO 2023) - "The patient was initially treated with metformin, but never achieved adequate glycemic control and experienced side effects. She was subsequently treated with sitagliptin and ertugliflozin, however, glycemic control remained inadequate (HbA1C 8.1%)... Activating mutations of ABCC8 gene are infrequent genetic causes of diabetes in adults. Sequencing of the ABCC8 gene should be considered in select adult patients, as diagnosis can guide management decisions.*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins."

Clinical • CNS Disorders • Developmental Disorders • Diabetes • Epilepsy • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus • HNF1A

Combination of Ertugliflozin And Sitagliptin Efficacy, Safety & Tolerability (CEASE Diabetes) Study (clinicaltrials.gov) - P=N/A | N=190 | Recruiting | Sponsor: Getz Pharma | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Drugs for type 2 diabetes. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Combination of Ertugliflozin And Sitagliptin Efficacy, Safety & Tolerability (CEASE Diabetes) Study (clinicaltrials.gov) - P=N/A | N=190 | Not yet recruiting | Sponsor: Getz Pharma

New trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Review of pharmaceutical and therapeutic approaches for type 2 diabetes and related disorders. (PubMed, Recent Pat Biotechnol) - "In the present review article, we have made an attempt to explore the risk factors, Genes, and diseases associated with T2D, therapeutic approaches in T2D, the influences of drugs such as Dapagliflozin, Metformin, Acarbose, Januvia (Sitagliptin), and Ertugliflozin on T2D in clinical trials and animal model studies. Research in clinical trials has promising results that support the role of these drug approaches in T2D prophylaxis and ameliorate safety even though additional clinical research is still obligatory."

Journal • Review • Cardiovascular • Diabetes • Gene Therapies • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus • KCNQ1OT1 • TCF7L2

"انتظار می‌رود که Steglatro و Steglujan در ژانویه‌ و Segluromet در ماه فوریه‌ی 2018، در آمریکا با نسخه ی پزشک در دسترس بیماران قرار گیرد..سعی کنید از این دارو به دقت استفاده کنید@merck #bigpharma" (@alidoki1)

Comparative Efficacy of Dual and Single Initiation of Add-On Oral Antihyperglycemic Agents in Type 2 Diabetes Uncontrolled on Metformin Alone: A Systematic Literature Review and Network Meta-Analysis. (PubMed, Diabetes Ther) - "For reduction of HbA1c, weight, and SBP in patients uncontrolled on metformin, add-on dual AHAs showed greater improvement compared to single AHAs. These findings can further inform the treatment of T2DM patients uncontrolled on metformin."

Clinical • Journal • Retrospective data • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Ertugliflozin alone and in fixed-dose combinations : «pass of three» (PubMed, Rev Med Liege) - "This SGLT2i is also available in fixed-dose combinations, ertugliflozin-metformin and ertugliflozin-sitagliptin. The three presentations offer a greater flexibility to the practitioner to optimize therapeutic choices for a complex disease where the treatment should be individualized according to the patient profile."

Journal • Cardiovascular • Diabetes • Hypoglycemia • Metabolic Disorders • Mycosis Fungoides • Type 2 Diabetes Mellitus

Bioequivalence of Ertugliflozin/Sitagliptin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components. (PubMed, Clin Pharmacol Drug Dev) - "The 4 studies demonstrated that each strength of FDC tablet is bioequivalent to the respective dose of coadministered individual components. This indicates that the known efficacy and tolerability of ertugliflozin and sitagliptin when coadministered can be translated to the use of a FDC formulation."

Clinical • Journal • Diabetes • Metabolic Disorders

Dapagliflozin/saxagliptin (Qtern) for type 2 diabetes. (PubMed, Med Lett Drugs Ther) - No abstract available.

Journal • Biosimilar • Diabetes

Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed-Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin. (PubMed, Clin Pharmacol Drug Dev) - "Ertugliflozin and ertugliflozin/sitagliptin FDC tablets can be administered without regard to meals. As metformin is administered with meals because of its gastrointestinal side effects, the ertugliflozin/metformin FDC should also be administered with meals."

Journal • PK/PD data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects. (PubMed, Clin Pharmacol Drug Dev) - "All treatments were well tolerated. The lack of clinically meaningful pharmacokinetic interactions demonstrates that ertugliflozin can be coadministered safely with sitagliptin, metformin, glimepiride, or simvastatin without any need for dose adjustment."

Clinical • Journal • Diabetes • Type 2 Diabetes Mellitus

Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus. (PubMed, Curr Med Res Opin) - P3 | "In an active-comparator study, when initiated as a single agent, the change from baseline in HbA1c at Week 52 was -0.5%, -0.7%, and -0.5% for ertugliflozin 5 mg, ertugliflozin 15 mg, and glimepiride, respectively...In an active-comparator study, when initiated in combination with sitagliptin, the change from baseline in HbA1c at Week 26 was -1.4%, -1.6%, and -0.9% for ertugliflozin 5 mg/sitagliptin, ertugliflozin 15 mg/sitagliptin, and sitagliptin alone, respectively...: Ertugliflozin, administered as a single agent or as combination with sitagliptin, improved HbA1c, BW, and SBP. Ertugliflozin was generally well-tolerated in Hispanic/Latino patients with T2DM."

Clinical • Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Drugs for type 2 diabetes. (PubMed, Med Lett Drugs Ther) - No abstract available.

Journal • Review

UPLC-MS/MS method for the quantification of ertugliflozin and sitagliptin in rat plasma. (PubMed, Anal Biochem) - "Matrix effect, extraction recovery, and stability data were in line with the stipulated FDA guidelines for validating a bioanalytical method. The validity of the designed method was confirmed through the pharmacokinetic experiments."

Journal • Preclinical

Approaches To Therapy Escalation In T2D (clinicaltrials.gov) - P4; N=0; Withdrawn; Sponsor: LMC Diabetes & Endocrinology Ltd.; Not yet recruiting ➔ Withdrawn; Trial primary completion date: Mar 2020 ➔ Sep 2019

Clinical • Trial primary completion date • Trial withdrawal

Ertugliflozin for the treatment of type 2 diabetes. (PubMed, Drugs Today (Barc)) - "It was granted approval by the U.S. Food and Drug Administration (FDA) in December 2017 for treatment of T2DM as a monotherapy, and as part of two separate fixed-dose combination therapies with sitagliptin (Steglujan) and metformin (Segluromet). It also has a longer half-life (16.6 hours) than presently available gliflozins, which translates into single daily dosing and dose reduction allowing for patient compliance. This review will focus on the preclinical pharmacology, pharmacokinetics, clinical efficacy and safety of ertugliflozin."

Journal

Ertugliflozin for type 2 diabetes. (PubMed, Aust Prescr) - No abstract available.

Journal • Review

ATTACC: Approaches To Therapy Escalation In T2D (clinicaltrials.gov) - P4; N=600; Not yet recruiting; Sponsor: LMC Diabetes & Endocrinology Ltd.

Clinical • New P4 trial